Calciphylaxis– Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Calciphylaxis, or calcification uremic arteriolopathy, is a rare disease thought to occur due to arteriolar calcifications of the dermis and is responsible for ischemia with cutaneous necrosis and painful panniculitis.
Etiology-
The cause of
calciphylaxis is not properly understood. The primary event is occlusion of the
small blood vessels in the skin by a thrombus (blood clot), which results in
spreading ischaemia and skin necrosis. It is thought that the clots occur
because of calcification within the walls of the blood vessels.
Epidemiology-
Calciphylaxis incidence rate of 3.49 per 1000
patient-years among the patients with end-stage renal disease (ESRD) on chronic
hemodialysis.
The competitive
landscape of Calciphylaxis includes country-specific approved as well as
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are being tracked and supplemented with analyst commentary.
KOLs
insights of Calciphylaxis across 8 MM market from the center of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Calciphylaxis
Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake, Attribute
Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and
Insights.
Comments
Post a Comment